The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world's population.
A new primate study published in the journal Nature in January 2020, reports that the almost century-old BCG vaccine against tuberculosis, may be used differently to achieve better protection against lung tuberculosis. While more work remains to be carried out before the findings can be accepted as the basis for clinical practice, they are extremely promising in the fight against this killer.
Researchers have found that the BCG vaccine is more efficacious in the prevention of TB when administered intravenously.
Worldwide, more people die from tuberculosis than any other infectious disease, even though the vast majority were vaccinated.
A new study published in the journal Scientific Reports says that for the first time a vaccine has been created against bovine tuberculosis that can be given without affecting the ability to diagnose tuberculosis later using the PPD skin test.
Seattle Children's Research Institute is one of three recipients of $30 million in first-year-funding provided by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to establish centers for immunology research to accelerate progress in tuberculosis vaccine development.
A team of researchers in the Department of Microbiology, Immunology and Pathology at Colorado State University aim to advance what is known about the complex immune response necessary to prevent tuberculosis disease.
The San Antonio Medical Foundation has awarded Texas Biomedical Research Institute Professor Jordi B. Torrelles, Ph.D., with a $173,000 grant to study a modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine shown to have promise for treating bladder cancer.
A new study published on October 29, 2019, in the New England Journal of Medicine, reports a new vaccine which could change the face of tuberculosis prevention. The disease kills 1.5 million people worldwide each year.
A common tuberculosis vaccine could decrease the risk of lung cancer if administered during early childhood, according to a study published Sept. 25 in JAMA Network Online.
Scientists working on a new tuberculosis vaccine have achieved a major step forward by showing that a promising TB antigen and a novel vaccine adjuvant can be protected from heat damage with a technique developed at the University of Bath.
For years, scientists have been trying to come up with a better way to protect people against tuberculosis, the disease caused by infection with the Mycobacterium tuberculosis bacteria.
Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.
GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.
Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of two TB vaccines-- the currently available BCG vaccine and an investigational vaccine, H4:IC31--in the New England Journal of Medicine (NEJM).
LSTM's Dr Maxine Caws is co-lead investigator on an advanced genetics study published in Nature Genetics(link is external), which has shown that a virulent strain of tuberculosis (TB) has adapted to transmit among young adults in Ho Chi Minh City, Vietnam.
Tuberculosis (TB), an infectious disease which attacks the lungs, claims someone's life every 20 seconds and 1.5 million lives worldwide every year.
Childhood asthma is a serious public health challenge in Québec and throughout the world. Although the immune mechanisms implicated in the development of childhood asthma are not fully understood, some studies seem to suggest that the BCG vaccine, used in tuberculosis prevention, may have a protective effect on childhood asthma.
Previously thought to be effective for 10-15 years, a new case-control study found that if given in early teenage years (12-13), the Bacillus Calmette-Guérin (BCG) vaccine protected over 50% of UK children against TB for at least 20 years, then waned.
Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association.